The Rising Protein Expression Market

Protein expression market in terms of revenue is poised to reach USD 5.4 billion by 2027, growing at a CAGR of 13.3%

The global protein expression market is expected to experience substantial growth in the coming years, projected to expand from $2.9 billion in 2022 to $5.4 billion by 2027 at a compound annual growth rate (CAGR) of 13.3%. This burgeoning market is driven by several key factors, including the increasing demand for protein biologics, particularly in the treatment of chronic diseases such as cancer, autoimmune disorders, and other serious conditions.

As the life science and biopharmaceutical industries continue to thrive, the focus on recombinant protein expression and the availability of investments for protein-based research are providing further impetus to the market’s growth. However, the high cost of protein expression reagents and instruments remains a restraining factor, potentially limiting adoption in certain areas.

Download a PDF Brochure: https://www.marketsandmarkets.com/pdfdownloadNew.asp?id=180323924

One of the notable trends shaping the market is the emergence of microfluidics, an advanced technique offering robust solutions for protein expression studies and analysis. Microfluidic technologies, such as droplet-based microfluidic (DBM) high-throughput screening and microfluidic antibody capture (MAC) chips, are enabling more efficient and precise evaluation of protein expression levels and protein modifications.

While the market faces challenges related to undesired post-translational modifications and the complexities of protein purification, the mammalian cell expression system segment continues to dominate, driven by its low cost and ease of use.

Geographically, North America currently leads the protein expression market, propelled by the region’s strong biotechnology and pharmaceutical industries, the prevalence of chronic disorders, and increased investments in protein-based therapeutics research.

Key players in the global protein expression market include Thermo Fisher Scientific, Merck KGaA, GenScript Biotech Corporation, Agilent Technologies, Danaher Corporation, Sartorius AG, Takara Bio, Bio-Rad Laboratories, Lonza Group AG, Promega Corporation, New England Biolabs, and Oxford Expression Technologies Ltd.

As the demand for protein biologics continues to surge and technological advancements unlock new possibilities, the protein expression market is poised for sustained growth, driving innovation and propelling the development of groundbreaking therapeutics.

Based on geography, the global protein expression market is segmented into Asia, Europe, North America, and Rest of the World (RoW). Of these, the Asian segment that includes the regional segments of China, India, Japan, and Rest of Asia (RoA) is expected to grow at the highest CAGR between 2013 and 2018. The growth in the Asian economies, particularly in China and India along with the increasing investments in biotechnology in Asia will be the major drivers for growth in the Asian protein expression market. In addition, the Asian region has witnessed an upward trend in the proteomics market over the past few years as many North American and European pharmaceutical drug manufacturers find it cost-effective to outsource their proteomics-based work to Asian manufacturers or set up their own manufacturing facilities in the Asian countries.

Thus, on account of the rise in demand of biologics, therapeutic proteins emerge as a lucrative revenue pocket. The demand for therapeutic proteins will handsomely reward investments made in the therapeutic protein industry. In the forecast period between 2013 and 2018, contract research organizations will provide generous returns on investments on account of the rising trend in outsourcing of research activities. Similarly, the economic developments in the Asian region will make the Asian countries one of the most lucrative revenue pockets in the global protein expression market. Investments made in the Asian proteomics industry will reap heavy dividends.